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background: The objective of this study was to identify baseline predictors of live birth in anovulatory patients undergoing ovulation
induction, and based on these predictors, develop nomograms for estimation of the probability of live birth in a single cycle.
methods: Univariate and multivariate logistic regression were used for retrospective analysis of clinical, sonographic and
endocrinological parameters collected prior to the start of ovarian stimulation in a cohort of anovulatory World Health Organization
(WHO) Group II patients (n ¼ 335), who were resistant to clomiphene citrate (CC) and therefore stimulated with gonadotrophins using
a low-dose step-up protocol.
results: The univariate analysis identiﬁed age [OR ¼ 0.91 (95% CI: 0.84–0.98), P ¼ 0.015], duration of infertility [OR ¼ 0.71 (95% CI:
0.56–0.91), P ¼ 0.007], serum follicle stimulating hormone (FSH) concentration at the start of stimulation [OR ¼ 0.83 (95% CI: 0.69–0.99),
P ¼ 0.034] and menstrual cycle pattern (P ¼ 0.022) as signiﬁcant predictors of live birth. Baseline concentrations of luteinizing hormone,
androgens, glucose and insulin, as well as body mass index, were not predictors of live birth. In the multivariate analysis, duration of infertility,
FSH and menstrual cycle pattern were independent predictors, and nomograms were designed with these three parameters for individual
prediction of the probability of live birth.
conclusions: The chances of live birth in women with WHO Group II anovulatory infertility resistant to CC undergoing ovulation
induction with gonadotrophins is highly inﬂuenced by the menstrual cycle pattern. Increases in duration of infertility and concentration of
FSH (within the normal range) before the start of stimulation have negative inﬂuences on the likelihood of achieving a live birth.
Key words: anovulation / gonadotrophin / live birth / nomogram / prediction model
Introduction
Chronic anovulation is a frequent cause of infertility in women. Most
of these women have irregular menstrual cycles but serum concen-
trations of follicle stimulating hormone (FSH) and estradiol (E2)
within the normal range, and are classiﬁed as World Health Organ-
ization (WHO) Group II anovulatory patients (World Health Organ-
ization, 1993). For these normogonadotrophic anovulatory infertile
patients wishing to conceive, administration of the anti-estrogen clo-
miphene citrate (CC) to induce ovulation is the ﬁrst-line
pharmacological treatment, due to low costs and few complications
(Practice Committee, ASRM, 2006; Thessaloniki ESHRE/ASRM-
sponsored PCOS consensus workshop group, 2008). However,
this treatment does not always lead to pregnancy. In fact, 15–25%
of the anovulatory women are resistant to CC therapy and about
40–50% of the women ovulating after CC-treatment fails to con-
ceive following six ovulatory cycles (Kousta et al., 1997; Messinis
and Milingos, 1997; Homburg, 2005). Low-dose gonadotrophin regi-
mens have so far primarily been used to increase treatment success
in CC-resistant women (Homburg, 2005), with reported pregnancy
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of 40–75% in three to six cycles (Thessaloniki ESHRE/ASRM-
sponsored PCOS consensus workshop group, 2008; Li et al., 2010).
Efforts have been made to identify baseline characteristics that may
predict ovarian response and outcome of ovulation induction in WHO
II anovulatory infertile women (for review, see Fauser et al., 2008).
Female age, body mass index (BMI), menstrual cycle history (oligome-
norrhea versus amenorrhea), free androgen index, hirsutism score and
duration of infertility have been shown to correlate with various
outcome measures in CC cycles (Imani et al., 1998, 1999; Rausch
et al., 2009). A number of baseline parameters (BMI, response to
previous CC-treatment, the number of follicles, serum concentrations
of FSH, testosterone and androstenedione) have also been suggested
to be predictive of ovulation and somewhat differ from those predic-
tive of conception (woman’s age, testosterone and insulin-like-
growth-factor-I) in women with gonadotrophin-induced ovulation
(Imani et al., 2002; Mulders et al., 2003a).
The main objective of the present investigation was to identify base-
line predictors of live birth in CC-resistant normogonadotropic anovu-
latory patients undergoing ovarian stimulation with gonadotrophins. A
secondary objective was to develop nomograms based on these pre-
dictors for straightforward prediction of the probability of live birth in
individual patients.
Materials and Methods
Study population
Data collected from two randomized controlled trials in anovulatory
WHO Group II women (Platteau et al., 2006; Balen et al., 2007)w e r e
combined to create a large study cohort. These trials had ovulation rate
as a primary outcome measure after stimulation with different gonado-
trophin preparations using low-dose step-up protocols of uniform
pattern. The ovulation, pregnancy and live birth rates were similar in the
two trials. A total of 335 patients were recruited at 36 European fertility
centres (13 in Belgium, 9 in Denmark, 5 in Sweden and 9 in the UK). All
patients met the following inclusion criteria: chronic anovulation
(amenorrhoea or oligomenorrhea, or anovulation based on progesterone
concentrations in women with cycles of 21–35 days duration); failure to
ovulate with CC doses of at least 100 mg/day for at least 5 days or
failure to conceive after three cycles of ovulation induction with CC;
infertility for ≥1 year before randomization; age 18–39 years; BMI
19–35 kg/m
2; at least one patent tube documented within 3 years
prior to screening; a normal pelvis documented by a transvaginal ultra-
sound scan with respect to uterus, fallopian tubes and ovaries within
3 months prior to screening; early follicular serum FSH concentrations
between 1 and 12 IU/l, concentrations of prolactin and total testosterone
not suggestive of hyperprolactinaemia or androgen-secreting tumours; and
a male partner with a normal semen analysis or semen from a donor.
Study protocol
Stimulation treatment was started 2–5 days after a spontaneous or
progesterone-induced menstrual bleed with either highly puriﬁed urinary
menotrophin (MENOPUR; Ferring Pharmaceuticals A/S, Copenhagen,
Denmark), highly puriﬁed urinary FSH (BRAVELLE; Ferring Pharmaceuti-
cals A/S, Copenhagen, Denmark) or recombinant FSH (rFSH; follitropin
alfa, Gonal-F; Merck Sereno, Geneva, Switzerland). The starting dose of
gonadotrophin was 75 IU daily, which was maintained for 7 days. After
the ﬁrst 7 days, the dose was either maintained or increased by 37.5 IU
increments according to individual response. All subjects were maintained
on their speciﬁc dose level for at least 7 days. The maximum permitted
daily dose was 225 IU and the women were treated with the gonado-
trophin for a maximum of 6 weeks. A single dose of 5000 IU of human
chorionic gonadotrophin (hCG) (PROFASI, Merck Serono, Geneva,
Switzerland) was given to trigger ovulation when one follicle of ≥17 mm
or two to three follicles of ≥15 mm was achieved. Subjects were not
given hCG in either of the following situations: no follicular response
after 6 weeks of gonadotrophin treatment, or greater than or equal to
four follicles with diameters of ≥15 mm. Any medication for luteal
support (e.g. progesterone or hCG) was prohibited. Serum progesterone
was measured in the mid-luteal phase (6–9 days after hCG) and ovulation
was deﬁned as a progesterone concentration of ≥7.9 ng/ml (25 nmol/l).
Data analysis
All clinical, sonographic and endocrinological parameters assessed prior to
the start of stimulation was included in the univariate logistic regression
analysis with the dependent variable, live birth. Regarding menstrual
pattern, patients were analysed in three groups: amenorrhoea (absence
of bleeding for .6 months), oligomenorrhea (irregular bleedings with
intervals of .35 days but ≤6 months) and anovulatory cycles based on
progesterone concentrations in women with cycles of 21–35 days dur-
ation. The predictive value of each variable was summarized as an odds
ratio (OR) with 95% conﬁdence interval (95% CI). All variables with a
P-value of ,0.1 in the univariate regression analysis were included in
the secondary multivariate regression analysis. The multivariate model
was reduced stepwise and variables with a P-value of ,0.1 were kept
in the ﬁnal model. Model ﬁt was checked by the Hosmer and Lemeshow
goodness-of-ﬁt test. Internal validation in the form of bootstrapping was
performed to reduce the risk of over-ﬁtting (Steyerberg et al., 2001). A
linear shrinkage factor was estimated in 1000 bootstrap runs. In each
run, the model was selected in a stepwise selection with all variables
entered. The shrinkage factor was applied to adjust the ORs and 95%
CIs in the ﬁnal model. The predictive ability of the model was assessed
by determining the area under the receiver-operating characteristics
(ROC) curve. A similar bootstrap approach to the above was used to
derive the bias-adjusted ROC area. The relationship between infertility
duration, FSH and menstrual cycle pattern was evaluated by analysis of
variance (one-way ANOVA). Nomograms were designed on the basis
of patient characteristics for prediction of the individual chances of achiev-
ing a live birth for CC-resistant patients with oligomenorrhea, amenorrhea
or anovulatory cycles of 21–35 days duration. To avoid over-ﬁtting, the
nomograms were adjusted by the same shrinkage factor as for the ORs
in the ﬁnal model.
Results
There were 335 patients included in the present analysis and of them
283 (84.5%) ovulated. The clinical and ongoing pregnancy rates were
18.2 and 17.3%, respectively, ending in a live birth rate of 17.3%
(14.9% singleton). Patient characteristics, sonographic data and endo-
crine proﬁle prior to start of ovarian stimulation are shown in Table I.
Table II shows the results of the univariate analyses of the associ-
ation between the prestimulation characteristics and live birth in an
ovulation induction cycle with gonadotrophins. The age of the
woman [OR ¼ 0.91 (95% CI: 0.84–0.98), P ¼ 0.015], duration of
infertility [OR ¼ 0.71 (95% CI: 0.56–0.91), P ¼ 0.007] and serum
FSH concentration at start of stimulation [OR ¼ 0.83 (95% CI:
0.69–0.99), P ¼ 0.034] were found to be negatively associated with
live birth. The menstrual cycle history also had a signiﬁcant impact
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with oligomenorrhea, the lowest OR was obtained for women with
anovulatory cycles of 21–35 days [OR ¼ 0.33 (95% CI: 0.15–0.73)].
The pretreatment parameters that yielded P-values of ,0.1 in the
univariate analysis were entered into a multivariate logistic regression
analysis to develop a model for prediction of the chances of live birth
in individual patients. The parameters that were kept in the ﬁnal
model were menstrual cycle pattern (P ¼ 0.040), duration of infertility
(P ¼ 0.013) and serum FSH (P ¼ 0.062) (Table II). After internal vali-
dation by bootstrapping, the ORs and 95% CIs in the multivariate
model were adjusted for over-ﬁtting by a shrinkage factor of 19%.
The Hosmer and Lemeshow test gave an acceptable ﬁt (P ¼ 0.244).
The unadjusted ROC-AUC was found to be 0.69, and the
bias-adjusted ROC-AUC found by bootstrap re-sampling was 0.66
(95% CI: 0.59–0.73). A graphical presentation of the model is
shown in Fig. 1.
Table III shows the parameters that were predictors of live birth in
the multivariate logistic regression model, in relation to the type of
menstrual cycle pattern. The live birth rates ranged from 8.5% in
women with anovulatory cycles of 21–35 days duration to 16.4% in
women with amenorrhea and to 22.2% in oligomenorrheic women.
Duration of infertility was comparable between the three menstrual
cycle groups, but the serum FSH concentration was signiﬁcantly
higher in patients with anovulatory cycles of 21–35 days
duration (5.9+2.7 IU/l) than in patients with oligomenorrhea
(5.2+1.9 IU/l) or amenorrhea (4.6+1.8 IU/l).
The multivariate logistic regression model was used to design
nomograms for prediction of the chances of achieving a live birth
following gonadotrophin stimulation (categorized by every 10%
points) for a given anovulatory patient. Separate nomograms were
developed for the three menstrual cycle pattern categories (Fig. 2).
The estimated chance of live birth is reduced by increased duration
of infertility and an increasing concentration of FSH (within the
normal range) before start of stimulation for all three categories.
Discussion
This large multicentre study of 335 patients treated with strictly
deﬁned and monitored protocols showed that the three simple pre-
treatment parameters (i) duration of infertility, (ii) basal serum FSH
concentration and (iii) the menstrual cycle status were predictive of
live birth after ovulation induction with gonadotrophins in normogona-
dotropic anovulation. Since a P-value threshold of 0.1 was used in the
multivariate logistic regression model to minimize erroneous exclusion
of relevant predictors, FSH was included in the ﬁnal model although
this predictor was not statistically signiﬁcant at the 5% level
(P ¼ 0.062). Age, on the other hand, was not a predictor in the multi-
variate analysis (P . 0.1), which could be explained by the fact that
age could not add much to the model after considering the duration
of infertility. Neither the sonographic assessments such as antral fol-
licle counts and ovarian volume, patients characteristics such as BMI
and waist-to-hip ratio or several endocrine parameters including LH,
androgen concentrations nor those related to presence or absence
of hyperinsulinaemia were predictive of a successful treatment.
As also found in other studies, models for prediction of pregnancy
or live birth have a modest discriminatory power. In the predictive
model developed by van Wely et al. (2005), who studied 85 patients
with polycystic ovary syndrome treated for 272 cycles, the area under
the ROC curve was 0.72, similar to the value of 0.69 (or 0.66 when
bias-adjusted) in the present study.
As mentioned above, the present study analysed a single ovulation
induction cycle. Another, clinically relevant approach, is to study the
cumulative effects of repetitive treatment cycles, as shown by
Eijkemanns et al. (2003) who used a treatment algorithm with clomi-
phene followed by gonadotrophins to predict live birth in 240 patients,
or by van Wely et al. (2005) who studied ongoing pregnancies within 1
year after the start of gonadotrophin treatment in 85 patients.
........................................................................................
Table I Clinical, sonographic and endocrinological
parameters prior to start of ovarian stimulation of the
entire group of normogonadotropic anovulatory
patients (n 5 335).
Parameter Value
a Q1
b Q3
c
Clinical
Female age (years) 29 26 32
BMI (kg/m
2) 24.5 21.3 29.3
,25 53%
25–29.9 27%
≥30 20%
Waist-to-hip ratio 0.81 0.76 0.87
,0.85 68%
≥0.85 32%
Menstrual cycle status
Oligomenorrhea 54%
Amenorrhea 18%
Anovulatory cycles of 21–35 days 28%
Duration of infertility (years) 2.5 1.7 3.5
Previous pregnancy 38%
Failure to ovulate on CC 40%
Failure to conceive on CC 60%
Sonographic
d
Antral follicle count 17 8 28
Mean ovarian volume (cm
3) 6.9 4.9 9.9
Endocrinological
d
LH (IU/l) 6.1 4.4 9.3
FSH (IU/l) 5.0 4.2 6.2
Estradiol (pmol/l) 147 110 195
Prolactin (mg/l) 11 8.0 15
Androstenedione (nmol/l) 6.4 4.6 8.6
Total testosterone (nmol/l) 1.7 1.3 2.1
SHBG (nmol/l) 48 30 79
Glucose, normal
e 90%
Insulin, normal
e 71%
Insulin-to-glucose ratio 2.1 1.3 3.5
aData are median or percentage of patients.
b25th percentile.
c75th percentile.
dAt start of stimulation.
eAs deﬁned by central laboratory reference ranges.
1990 Nyboe Andersen et al.Similar to what is found in the present study, van Wely et al. (2005)
showed that the presence of oligomenorrhea and short duration of
infertility were associated with higher chances of an ongoing pregnancy
within 12 months. Thus, it is likely that the prediction based on results
from a single cycle can be extrapolated to the cumulative effects of
treatments over time. In relation to the endocrine predictors, a
lower free androgen index was associated with higher chances of an
ongoing pregnancy within 12 months (van Wely et al., 2005). The
study by Eijkemanns et al. (2003) suggested that older age, longer
duration of infertility and higher insulin-to-glucose ratio may be used
to identify poor prognosis patients.
In the meta-analysis of 13 studies of the outcome of ovulation
induction with gonadotrophins by Mulders et al. (2003b), the main
end-point was pregnancy. This meta-analysis found that the only
two parameters predictive of pregnancy were insulin resistance (pres-
ence or absence of hyperinsulinaemia) with an OR of 0.29 (95% CI:
0.10–0.80) and serum LH concentration with a pooled OR of 1.04
(95% CI: 1.01–1.07). However, the prediction of live birth may be
different, as this meta-analysis indicated that the miscarriage rate
was different in obese versus non-obese patients (OR 3.05; 95% CI:
1.45–6.44). In this context, it should be noted that neither the predic-
tion models by van Wely et al. (2005), Eijkemanns et al. (2003) and
.......................................................... ..........................................................
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Table II Univariate and multivariate analysis of the association between live birth and clinical, sonographic and
endocrinological parameters prior to start of ovarian stimulation, and type of gonadotrophin treatment in the entire
group of normogonadotropic anovulatory patients (n 5 335).
Parameter Univariate Multivariate
OR 95% CI P OR 95% CI P
Clinical
Female age (years) 0.91 0.84–0.98 0.015
BMI (kg/m
2) 1.01 0.95–1.08 0.673
Waist-to-hip ratio
a 1.15 0.90–1.48 0.271
Menstrual cycle pattern 0.022 0.040
Oligomenorrhea (reference) 1.00 1.00
Amenorrhea 0.69 0.32–1.47 0.63 0.32–1.22
Anovulatory cycles 0.33 0.15–0.73 0.45 0.23–0.88
Duration of infertility (years) 0.71 0.56–0.91 0.007 0.78 0.64–0.95 0.013
Previous pregnancy 0.77 0.43–1.41 0.402
Failure to conceive on CC 0.87 0.49–1.54 0.632
Failure to ovulate on CC 1.15 0.65–2.04 0.632
Sonographic
b
Antral follicle count 1.01 0.99–1.03 0.209
Mean ovarian volume (cm
3) 1.00 0.93–1.07 0.966
Endocrinological
b
LH (IU/l) 1.00 0.94–1.07 0.895
FSH (IU/l) 0.83 0.69–0.99 0.034 0.86 0.74–1.01 0.062
Estradiol (pmol/l)
c 0.92 0.83–1.02 0.111
Prolactin (mg/l) 1.01 0.98–1.03 0.696
Androstenedione (nmol/l) 0.99 0.92–1.07 0.818
Total testosterone (nmol/l) 0.91 0.57–1.44 0.678
SHBG (nmol/l) 1.01 1.00–1.01 0.142
Glucose, normal
d 2.16
e 0.63–7.35
e 0.219
e
Insulin, normal
d 1.11
e 0.59–2.08
e 0.756
e
Insulin-to-glucose ratio 0.94 0.83–1.07 0.331
Type of gonadotrophin
HP-FSH versus rFSH
f 0.84 0.37–1.89 0.674
HP-hMG versus rFSH
g 0.80 0.36–1.78 0.587
aSteps of 0.1.
bAt start of stimulation.
cSteps of 25 pmol/l.
dAs deﬁned by central laboratory reference ranges.
eNormal versus abnormal.
fBalen et al. (2007).
gPlatteau et al. (2006).
Outcome prediction for gonadotrophin-induced ovulation 1991Mulders et al. (2003b) nor the present model identiﬁed obesity (or
BMI) as a predictor of pregnancy or live birth rate in normogonadotro-
pic anovulatory women. An earlier analysis of the present study cohort
evaluated several treatment outcome parameters following ovulation
induction with gonadotrophins in non-obese versus obese women
and found no differences in pregnancy rates (Balen et al., 2006). It
thus seems consistent that BMI is not a predictor of either pregnancy
or live birth. Regarding other proposed predictors, hyperinsulinaemia
may be a factor (Mulders et al., 2003b), even though well-conducted
large trials with a rather homogeneous patient population with poly-
cystic ovarian syndrome and oligo- or amenorrhea (van Wely et al.,
2005) failed to show any association to live birth rates. Therefore,
our ﬁnding in the present large series does challenge the importance
of hyperinsulinaemia, at least in patients within a certain BMI range.
Since obesity is related to hyperinsulinaemia, the BMI range may be
important, as our study was restricted to patients with BMI below
35 kg/m
2.
In the present study, 28% of the patients were classiﬁed as having
normogonadotrophic anovulatory infertility with preserved menstrual
cyclicity of ,35 days. These patients had normal serum concen-
trations of FSH at baseline, and were included based on local assess-
ments of progesterone suggesting non-ovulatory cycles. However, as
evident from Table III, such patients had a signiﬁcantly higher FSH con-
centration and lower live birth rate (8.5%) than oligomenorrheic
(22.2%) and amenorrheic patients (16.4%), even though it could be
anticipated that the degree of ovulatory disturbance would be less
severe in this group of patients. Given the less stringent criteria for
including these patients based on progesterone assessments in
Figure 1 ROC curve displaying sensitivity and speciﬁcity of the predictive model in the whole study cohort (n ¼ 335).
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Table III Relationshipbetween menstrual cycle pattern, livebirth and the parametersthat were predictors of live birth in
the multivariate logistic regression model.
Parameter All patients
n 5 335
Menstrual cycle pattern P-value
a
Oligomenorrhea
(n 5 180) (54%)
Amenorrhea
(n 5 61) (18%)
Anovulatory cycles of 21–35
days (n 5 94) (28%)
Live birth 17.3% 22.2% 16.4% 8.5% 0.022
Duration of infertility
(years)
2.9+1.8 2.7+1.6 3.1+2.8 3.0+1.4 0.390
FSH (IU/l) 5.3+2.2 5.2+1.9 4.6+1.8
b 5.9+2.7
c,d 0.001
aThe relationship between menstrual cycle pattern and live birth was evaluated by logistic regression. The relationships between menstrual cycle pattern and duration of infertility and FSH
were evaluated by one-way ANOVA, and individual groups were compared with Student’s t-test.
bP , 0.07 versus oligomenorrhea.
cP , 0.01 versus oligomenorrhea.
dP , 0.001 versus amenorrhea.
1992 Nyboe Andersen et al.Figure 2 Nomograms for estimation of the probability of live birth in a single cycle after ovulation induction with gonadotrophins in normogonado-
tropic patients with oligomenorrhea, amenorrhea or anovulatory menstrual cycles of 21–35 days duration.
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patients with preserved cycles had additional but concealed infertility
factors that may explain part of the poorer prognosis. Thus, patient
heterogeneity may be present and may explain the differences regard-
ing FSH as a predictor. However, the meta-analysis of available studies
by Mulders et al. (2003b) also included studies with patients who had
anovulatory cycles as well as some with patients who had earlier
ovarian electrocautery. Furthermore, the possible predictive value of
basal FSH was also analysed by Eijkemanns et al. (2003) in patients
treated with a classical ovulation induction protocol; ﬁrst with CC fol-
lowed by gonadotrophins. In that study, basal FSH tended to be a sig-
niﬁcant predictor of pregnancy (P ¼ 0.07), but basal FSH was higher in
the pregnant than in the non-pregnant group. Another possibility is
that the slightly higher FSH concentrations observed in our patients
with no live birth reﬂect that some of these patients may have a
minor increase in ovarian age. As reviewed by Hendriks et al.
(2005), increased FSH concentrations do have some, even though
low, predictive value for achievement of pregnancy following assisted
reproductive technology (ART). The same may be true for ovulation
induction.
In order to increase the clinical usefulness of the ﬁndings in the
multivariate model, prediction nomograms were developed in
the present study (Fig. 2). As three independent predictors were
found, two-dimensional nomograms were constructed showing the
prediction in relation to duration of infertility and basal FSH for
each menstrual cycle pattern. To illustrate how the nomogram may
be used an oligomenorrheic patient with 3 years of infertility and a
basal FSH of 3 IU/l will have a predicted chance of live birth
between 20 and 30% for a single cycle. In contrast, an anovulatory
patient with 21–35 days cycle duration with 4 years of infertility
and a basal FSH of 6 IU/l is predicted to have a low chance of live
birth of ,10%.
On the basis of our nomograms, the predicted live birth rates
may thus vary 3-fold between patients with different characteristics.
On the basis of registry data of in vitro fertilization (Templeton et al.,
1996), similar or even larger differences in prognosis are present
among patients treated with IVF. Our data should be used to
encourage couples with a good prognosis, such as short duration
of infertility and oligomenorrhea, to undergo ovulation induction
treatment. Additionally, it is likely that such couples would beneﬁt
from several treatments cycles (Eijkemanns et al., 2003) if the ﬁrst
few do not provide a pregnancy. The concern is how to advice a
couple who according to our data are predicted to have a chance
of live birth of ,10% per attempt, as patients with characteristics
such as a high FSH, long duration of infertility and perhaps minor
ovulatory disturbances also have a low chance of live birth with
ART (Templeton et al., 1996). Irrespective of such considerations,
our nomogram may allow couples to be appropriately informed
about their prognosis, and thus make a fully informed decision on
treatment.
In summary, extensive endocrine testing in anovulatory WHO
Group II patients undergoing ovulation induction with gonadotrophins
was of little use in relation to prediction of live birth, as only basal FSH
concentration was an independent endocrine predictor. In contrast,
the simple clinical parameters relating to duration of infertility and
menstrual cycle pattern were important determinants of successful
outcomes.
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